|Awarded On||August 20, 2014|
|Title||Novel, Humanized Single-Chain CD123xCD3 Bispecific Antibodies for Eliminating Leukemia Stem Cells and Leukemic Cells|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Scott and White Healthcare|
|Principal Investigator/Program Director||Jung H Woo|
Acute myeloid leukemia (AML) is the most common leukemia and its overall 5-year life expectancy rate is low. Poor survival of AML is often due to drug resistant cancer cells called leukemia stem cells (LSC). LSC often become resistant to drugs because they have proteins that allow them to avoid cell death from drugs. One protein found on LSC that promote tumor cell survival is called CD123. Researchers have targeted CD123 before as a way to target and kill LSCs. Results from two clinical trials for drugs targeting CD123 produced encouraging results in that the drugs did not cause major side effects and showed some effect in killing LSC and tumor cells. The drug being developed here builds up...